Neurocrine Biosciences (NASDAQ: NBIX) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Volatility & Risk
Neurocrine Biosciences has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 3.14, meaning that its share price is 214% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Neurocrine Biosciences and Sangamo Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neurocrine Biosciences presently has a consensus target price of $68.81, suggesting a potential upside of 10.72%. Sangamo Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 0.33%. Given Neurocrine Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Sangamo Therapeutics.
Institutional & Insider Ownership
63.4% of Sangamo Therapeutics shares are held by institutional investors. 4.8% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 5.5% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Neurocrine Biosciences and Sangamo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Neurocrine Biosciences and Sangamo Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Neurocrine Biosciences||$6.34 million||864.83||-$219.96 million||($2.52)||-24.66|
|Sangamo Therapeutics||$23.42 million||53.37||-$57.47 million||($0.81)||-18.46|
Sangamo Therapeutics has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics beats Neurocrine Biosciences on 8 of the 13 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.